Back

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

30 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Translating improved disease understanding to novel therapies in myocardial disease Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)

6 More presentations in this session

Presentation thumbnail
Macrophage-derived SPP1 exacerbate myocardial injury by interacting with fibroblasts in viral myocarditis
Professor B. Han (Jinan, CN)
Abstract Slides Video
Presentation thumbnail
Clonal haematopoiesis of indeterminate potential and incident cardiomyopathy
Doctor Y. Yu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Cardiac radiation suppresses hypertrophic cardiomyopathy phenotyping in TnT R92Q HCM mice via modulating Ca2+ homeostasis
Doctor Y. Huang (Changsha, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of monoclonal antibodies targeting interleukin-5 and interleukin-4/13 pathways in eosinophilic myocarditis: a single-center experience.
Doctor C. Menghi (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Amyloid staining for detection of eosinophil granules in cardiac tissue
Doctor T. Kumaki (Niigata, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Translating improved disease understanding to novel therapies in myocardial disease

The Event

Event poster

ESC Congress 2025

30 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM
13 May 2024
thumbnail
Congress Session
Contemporary management of hypertrophic cardiomyopathy
27 August 2023
thumbnail
Congress Presentation
REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM trials: Incidence and impact of atrial fibrillation in oHCM with aficamten
31 August 2025
thumbnail
Congress Presentation
Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources